Increasing HPV vaccine uptake among young patients
Official title: Human Papillomavirus Ends Here: A Multilevel Intervention to Increase Uptake of the HPV Vaccine Among Adolescents
Run by University of California, Davis · NCT06831929 · Data updated 2026-11-12
This study is testing a new approach to help more young patients aged 10-12 get the HPV vaccine at clinics in California.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 10 Years to 12 Years |
| Sex | All |
| Enrollment | 2232 (estimated) |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Status | Recruiting |
| Started | February 28, 2025 |
| Main results expected | February 5, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT06831929 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 10-12 who are eligible for the HPV vaccine.
✕Probably not a fit
Patients who have already received the HPV vaccine or have contraindications to it will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop and evaluate a culturally tailored multilevel intervention designed to increase the uptake of the HPV vaccine among eligible patients aged 10-12 at the University of California, Davis Health Community Physician practices. The intervention will be refined through qualitative interviews with stakeholders and implemented in a randomized controlled trial across twelve clinics. The effectiveness of the intervention will be assessed by comparing HPV vaccine completion rates between the intervention and control groups using electronic medical records.
Why it matters
Potential benefit: If successful, this intervention could significantly increase the HPV vaccination rates among adolescents, leading to better prevention of HPV-related diseases.
How similar studies have gone: Other studies have shown success in increasing vaccination rates through tailored interventions, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • Clinic patients between the ages of 10-12 who are eligible for the HPV vaccine Exclusion Criteria: • Clinic patients who already received the HPV vaccine or with any contraindication to the HPV vaccine.
Where it's running
-
University of California Davis Health
Sacramento, California, United States Recruiting
Study contacts
- Principal investigator: Julie HT Dang, PhD, MPH — University of California, Davis
- Study coordinator: Julie Dang, PhD, MPH
- Email: jtdang@health.ucdavis.edu
- Phone: 9167345222
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Digital tools to boost HPV vaccination intentions among Nigerian caregivers
This study tests whether different online content can help Nigerian parents of unvaccinated girls ages 9-14 decide to vaccinate their daughters against HPV.
-
HPV Immunization in Ghana to See if Vaccine Works in Babies and Teens
This study tests whether a bivalent HPV vaccine is safe and can provoke an immune response in healthy infants and young children, and compares it to responses seen in unmarried young women aged 15–20 in Ghana.
-
Six-year antibody response after one dose of the 9‑valent HPV vaccine in students
We will test whether one dose of the 9‑valent (9vHPV) vaccine given to 9–11‑year‑old students in 2019–2020 still produces antibodies six years later.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.